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INTRAVITREAL TRIAMCINOLONE ACETONIDE AS
ADJUNCTIVE TREATMENT FOR NEOVASCULAR
GLAUCOMA
Maria Teresa Brizzi Chizzotti Bonanomi, and Remo Susanna Jr.
Neovascular glaucoma is a challenging disease in its
pathogenesis and treatment.1-3 Ischemic retinopathies can
lead to neovascular glaucoma due to newly formed vessels
on the iris surface and anterior chamber angle. Eyes with
neovascular glaucoma can exhibit high intraocular pressure,
usually treated by retinal coagulation, cyclodestructive pro-
cedures, or drainage procedures.3,4 Based on experimental
studies, clinical observations, and pathogenetic considera-
tions, Robert Machemer proposed the intravitreal applica-
tion of crystalline cortisone to locally suppress intraocular
inflammation, proliferation of cells, and neovascula-
rization.5-7 The purpose of the present clinical study is to
report on a new potential treatment modality, the
intravitreal injection of triamcinolone acetonide as adjunc-
tive therapy of secondary neovascular glaucoma.
CASE REPORT
A 70-year-old caucasian diabetic woman presented with
poor vision in both eyes in September, 2003. Her past ocu-
lar history comprised cataract surgery and laser photoco-
agulation in both eyes for diabetic retinopathy and in the
right eye for associated venous occlusion. The diabetes and
the high blood pressure were poorly controlled, and creati-
nine clearance and HbA1c were 60 mL/min and 15%, re-
spectively. Her visual acuity was counting fingers in the
right eye (RE) and 20/200 in the left eye (LE). The
intraocular pressure (IOP) was 13 mm Hg in the RE and 14
mm Hg in the LE. The fundus showed bilateral panretinal
photocoagulation (PRP) and clinically significant macular
edema but no retinal neovascularization (Fig.1). An
intravitreal triamcinolone injection was proposed initially
for the right eye. An intravitreal injection of 4 mg (0.1 mL)
triamcinolone acetonide (Kenalog-40, Apothecon,
Princeton, NJ) was performed through the pars plana. After
the procedure (October 17, 2003), her vision did not im-
prove despite the partial drying of the macula, and the
intraocular pressure ranged from 12 to18 mm Hg up to Feb-
ruary 25, 2004. The LE was treated only with extra periph-
eral and macular photocoagulation. On March 10, 2004, the
patient returned with a severe pain in the RE associated
with nausea. Iris neovascularization, cornea edema with
poorly visible fundus, and an IOP of 54 mm Hg was de-
tected. A second intravitreal injection of 4 mg triamci-
nolone was given on that day, along with transconjunctival
cryotherapy in the peripheral retina (5 applications per
quadrant). The medical treatment comprised 0.5% timolol
maleate and 1% atropine locally and oral acetazolamide.
After 2 days, the patient returned with no pain, an IOP of
Figure 1 - Angiofluoresceinography of both eyes in September 2003.
A – The right eye shows dilated veins alongside the background diabetic
retinopathy. Laser marks and large areas of capillary nonperfusion are
visible throughout the mid-peripheral retina. B – The left eye shows
the diabetic background retinopathy and a less coarse laser pattern
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24 mm Hg, no corneal edema, and barely visible iris
neovascularization. In the fundus, a progression of the vas-
cular occlusion was visible, now compromising the retinal
arteries (Fig.2), and PRP was intensified. In the following
visits (April 16, 2004 and May 24, 2004), the IOP was 22
mm Hg with 1% brinzolamide, 0.5% timolol maleate, and
1% atropine. The angle was free from goniosynechia in
about 120o, and the vision remained the same.
DISCUSSION
One of the most important still unsolved problems in
clinical ophthalmology is the proliferation of vascular cells
in eyes with intraocular neovascular diseases. The new ves-
sels on the iris surface and anterior chamber angle are sec-
ondary to ischemic and, to a lesser degree, to inflammatory
retinal diseases.1 Once established, this entity is difficult
to manage surgically .2 The arresting of the neovascular
process through retinal destructive techniques is the only
known treatment.3 Even though retinal ablation has an ef-
ficacy of about 85% using cryosurgery or laser surgery;
neovascular glaucoma may still appear in 1.6% of treated
eyes.4 A specific pharmacological therapy for intraocular
neovasularization control or regression is not still available.
For many years, corticosteroids have been known to reduce
intraocular inflammation and, depending on the concentra-
tion, to suppress cell proliferation. Consequently,
corticosteroids, given either locally or systemically, have
been used in many ocular conditions. To achieve the high-
est concentration of a drug at its site of action, however, it
is best to give it directly into the area where this action is
required. Based on experimental studies that showed ster-
oid inhibition of appearance and growth of neovascular tis-
sue in the eye due to inflammation5-8 and ischemia,9 along
with its few described side effects.10,11Jonas et al. proposed
the intravitreal injection of crystalline cortisone as an ad-
junctive therapy to manage neovascular glaucoma.12 They
reported using a single injection of approximately 20 mg
of triamcinolone acetonide with little vehicle in patients
with established neovascular glaucoma. Associated proce-
dures included goniosynechiolysis, phacoemulsification
and intraocular lens implantation, and transscleral periph-
eral retinal cryocoagulation. After a follow-up period of 3.10
± 2.4 months, they showed a significant decrease of the de-
gree of rubeosis iridis, improvement in intraocular pressure,
and no significant changes in visual acuity.
Recently, a smaller amount of triamcinolone (0.1 mL of
40 mg/mL) with no previous filtration has been injected
into the vitreous, to control macular edema secondary to
diabetes,13 central retinal vein occlusion (CRVO),14 and in-
flammatory disease.15 Despite the potentially vision-threat-
ening complications such as transient or persistent
intraocular high pressure,16 cataract progression,13 and asep-
tic17 or septic endophthalmitis,18 the gravity of the clinical
condition of our patient seemed to justify this procedure.
We performed a single injection of 4 mg of the commer-
cially available triamcinolone acetonide through the pars
plana along with transconjunctival cryotherapy. Our patient
received 2 injections, and it may be speculated that the first
injection caused a worsening of the neovascular process.
Although it has frequently been a surgical approach,
intravitreal corticosteroid injection has not been associated
with this complication in the literature.13-20 Ip et al.,20 retro-
spectively studying 13 patients treated with 4 mg
intravitreal triamcinolone injections to control macular
edema due to central retinal vein occlusion, reported a sec-
ond injection in 3 patients and 1 eye that developed iris
neovascularization after the treatment. In our patients, in
the 2 days after the injection, the iris neovascularization
was barely visible, the corneal edema was gone, and we
could complete the PRP through clear media. It has to be
taken into account that the duration of the anti-angiogenic
effect of the intravitreal steroids is limited about 2 weeks
experimentally21,22 and from 2 to 5 months clinically13,14 if
not supported by additional procedures such as panretinal
photocoagulation.
In the present case, it is unlikely that the rapid iris
neovascularization regression, as well as the reduction in
IOP, was caused solely by the retinal cryocoagulation.
Though consistently stating the efficacy of this method of
treatment for anterior segment neovascularization or early
neovascular glaucoma, the literature is not clear about the
time span in which neovascularization regression takes
place.23-25 Using the panretinal cryotherapy (10 to 14 ap-
Figure 2 - Color retinography of the right eye after the cryoablation
and the intravitreal injection. Two days before this picture, before the
treatment, the cornea was edematous and the fundus barely visible.
Vascular changes such as venous sheathing, intravascular stop of the
blood column, arteriolar thinning, retinal hemorrhages, and cotton
wool spots were also visible throughout the entire fundus
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plications per quadrant), the regression of the rubeotic ves-
sels begins after a few days of treatment, with complete reso-
lution occurring after 4 to 6 weeks. 23,24 Using the
transconjuntival anterior retina cryoablation, Sihota et al.25
report a rapid release of pain and iridocyclitis, with the cor-
neal edema regressing over a period of 7 to 10 days. In our
patient, after 48 hours of the treatment pain, iris
neovascularization and corneal edema were all gone, leav-
ing a perfect environment for further retinal photocoagula-
tion (Fig. 2).
The results of this study support the findings of previ-
ous investigations and clinical observations.11 Using the
intravitreal cortisone injection associated with the cryo-
therapy, we gained time and were able to stop the process
of angle closure through retinal coagulation.
The outcome of this case, as well as evidence from
the literature, suggests that the intravitreal application
of triamcinolone acetonide helps to temporarily reduce
the neovascularization of the iris. With the normaliza-
tion of the intraocular pressure and clearing of the cor-
neal edema, laser application to the retina is possible
through clear media.
However, randomized prospective investigations are
needed to confirm our findings and to determine the
usefullness of the intravitreal injection of 4 mg of triamci-
nolone acetonide as an additional tool in the treatment of
neovascular glaucoma secondary to ischemic retinopathies.
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